Trillium, Biogen Idec in immunology deal

Trillium Therapeutics Inc. (Toronto, Ontario) granted Biogen Idec Inc. (NASDAQ:BIIB) exclusive, worldwide rights to develop and commercialize an undisclosed protein therapeutic in preclinical testing for immunology indications. Trillium will receive an undisclosed upfront payment and is eligible for milestones and royalties.

Separately, Biogen Idec submitted an MAA to EMEA for Fampridine-PR to improve walking ability in adults with multiple sclerosis. The company also submitted an NDS in Canada, where the product is called Fampridine-SR. Biogen Idec has rights outside the U.S. to the sustained-release formulation of 4-aminopyridine from Acorda Therapeutics Inc. (NASDAQ:ACOR). In the U.S., the compound is under review as Fampridine-SR, with a PDUFA date of Jan. 22. ...